

B



JAN 16 2001

Peter S. Reichertz
Arent Fox Kintner Plotkin & Kahn, PLLC
1050 Connecticut Avenue, N.W.
Washington, D.C. 20036-5339

Re: Docket No. 78N-036L
Comments No. PRC2, CP7,
CP8, LET40, LET41, PDN9,
and C201/ANS


Dear Mr. Reichertz:

This is in response to your Petition for Reconsideration dated March 17, 2000, submitted on behalf of C.B. Fleet Company, Inc., and filed in FDA's Dockets Management Branch as Comment No. PRC2 under Docket No. 78N-036L. You referenced the agency's May 22, 1998 letter that denied two citizen petitions concerning bisacodyl as an over-the-counter (OTC) laxative (CP 7 and CP 8 under Docket No. 78N-036L), because of safety concerns. You stated that because the agency has now concluded that bisacodyl is safe, the agency should reconsider the May 22, 1998 denial and reinstate the findings of the two October 26, 1989 letters in which the agency proposed Category I (safe and effective) conditions for bisacodyl.

The Division of OTC Drug Products agrees with your Petition for Reconsideration to reinstate the findings of the October 26, 1989 letters. In a February 16, 2000 letter to Dr. Martin Kaplan, Boehringer Ingelheim, concerning results of carcinogenicity studies submitted to support the safety of bisacodyl, the Division stated that the totality of the data support the safety of bisacodyl for use as an OTC laxative. (See Comment No. C201/ANS, Docket No. 78N-036L.)

Therefore, the Division agrees that the Category I conditions discussed in the two October 26, 1989 letters in response to CP7 and CP8 (LET40 and LET41, respectively) be included in the final monograph for OTC laxative drug products as follows:

1. Rectal enema dosage: Adults and children 12 years of age and over: 10 milligrams bisacodyl in 37.5 milliliters of aqueous suspension in a single daily dose. Children under 12: ask a doctor.



2. A bowel cleansing kit containing the following 3 laxative drug products for sequential administration: dibasic sodium phosphate/monobasic sodium phosphate as an oral solution identified in § 334.16 and bisacodyl identified in § 334.18 in both an oral dosage form and a suppository dosage form.
3. A bowel cleansing kit containing the following 3 laxative drug products for sequential administration: dibasic sodium phosphate/monobasic sodium phosphate as an oral solution identified in § 334.16 and bisacodyl identified in § 334.18 in both an oral dosage form and an enema dosage form.

The Division of OTC Drug Products intends to recommend to the Commissioner that the agency respond to your petition for reconsideration in the above manner in the final monograph for OTC laxative drug products, which will be published in a future issue of the FEDERAL REGISTER.

Any comment you may wish to make on the above information should be submitted in three copies, identified with the docket and comment numbers shown at the beginning of this letter, to the Dockets Management Branch (HFA-305), Food and Drug Administration, 5630 Fishers Lane, Room 1061, Rockville, MD 20852.

Sincerely yours,



Linda M. Katz, M.D., M.P.H.
Deputy Director
Division of OTC Drug Products
Office of Drug Evaluation V
Center for Drug Evaluation
and Research

FACSIMILE TRANSMITTAL COVER SHEET

Date: January 19, 2001

No. of Pages: 4
(Including Cover Sheet)

PLEASE DELIVER TO:

Name:	Fax Number:	Verify Number:
Ms. Sarah S. Post	(804) 847-4219	(804) 528-4000
Mr. Douglas Bellaire	(804) 845-2066	(804) 528-4000
Joseph A. Kanapka, Ph.D.	(804) 528-1324	(804) 522-8454
Mr. William R. Parsanko	(804) 847-6110	(804) 528-4000
Mr. Ray Pennino	(804) 847-6110	(804) 528-4000

Attorney Number: 0160 **Client Number:** 009442-00005

Hard Copy Sent: Yes (via mail)

Comments:

Re: FLEET® Bisacodyl Enema and FLEET® Prep Kits

01
ENE 19 P 6:04

THIS FACSIMILE CONTAINS PRIVILEGED AND CONFIDENTIAL INFORMATION INTENDED ONLY FOR THE USE OF THE ADDRESSEE(S) NAMED ABOVE. IF YOU ARE NOT THE INTENDED RECIPIENT OF THIS FACSIMILE, OR THE EMPLOYEE OR AGENT RESPONSIBLE FOR DELIVERING IT TO THE INTENDED RECIPIENT, YOU ARE HEREBY NOTIFIED THAT ANY DISSEMINATION OR COPYING OF THIS FACSIMILE IS STRICTLY PROHIBITED. IF YOU HAVE RECEIVED THIS FACSIMILE IN ERROR, PLEASE IMMEDIATELY NOTIFY US BY TELEPHONE AND RETURN THE ORIGINAL FACSIMILE TO US AT THE ADDRESS BELOW VIA THE POSTAL SERVICE. THANK YOU

Please Call As Soon As Possible If Transmission Is Not Complete: 202/857-6119

Arent Fox Kintner Plotkin & Kahn, PLLC
1050 Connecticut Ave., N.W., Washington, D.C. 20036-5339

* * * COMMUNICATION RESULT REPORT (JAN. 19. 2001 6:33PM) * * *

TTI ARENT FOX DC1

Fl. MODE	OPTION	ADDRESS (GROUP)	RESULT	PAGE
5668	MEMORY TX	0160#009442#00005#18048474219#	OK	4/4
		0160#009442#00005#18048452066#	OK	4/4
		0160#009442#00005#18045281324#	OK	4/4
		0160#009442#00005#18048476110#	OK	4/4

REASON FOR ERROR
 E-1) HANG UP OR LINE FAIL
 E-3) NO ANSWER

E-2) BUSY
 E-4) NO FACSIMILE CONNECTION



Peter S. Reichertz
 Tel: 202/857-6378
 Fax: 202/857-6395
 reicherp@arentfox.com
 www.arentfox.com

FACSIMILE TRANSMITTAL COVER SHEET

Date: January 19, 2001

No. of Pages: 4
 (Including Cover Sheet)

PLEASE DELIVER TO:

Name:	Fax Number:	Verify Number:
Ms. Sarah S. Post ✓	(804) 847-4219	(804) 528-4000
Mr. Douglas Bellaire ✓	(804) 845-2066	(804) 528-4000
Joseph A. Kanapka, Ph.D. ✓	(804) 528-1324	(804) 522-8454
Mr. William R. Parsanko ✓	(804) 847-6110	(804) 528-4000
Mr. Ray Pennino ✓	(804) 847-6110	(804) 528-4000

Attorney Number: 0160 **Client Number:** 009442-00005